This study is designed to understand usage pattern and tolerability, including dosing frequency and treatment duration, of an oral pain relief drug in post-operative and non-surgical patients.
This is a decentralized, prospective, randomized controlled study. 1000+ adults will be recruited throughout 17 sites across five APAC countries—including Singapore, Thailand, Malaysia, Hong Kong, and the Philippines—to form a patient treatment registry. Patients prescribed the drug for moderate to severe acute pain (post-surgical or non-surgical) will be screened on-site and enrolled in the registry after signing an eIC. These participants will be required to use the ObvioHealth app for data entry upon leaving the site. Patients will complete validated questionnaires measuring pain intensity, medication adherence, perception, and change to health status.
For in-patient participants, site staff will collect and submit required data via the ObvioHealth app.
This study has only just begun, so there are no results available at this time. However, be sure to check back soon for relevant updates.
This study is designed to understand usage pattern and tolerability, including dosing frequency and treatment duration, of an oral pain relief drug in post-operative and non-surgical patients.
This is a decentralized, prospective, randomized controlled study. 1000+ adults will be recruited throughout 17 sites across five APAC countries—including Singapore, Thailand, Malaysia, Hong Kong, and the Philippines—to form a patient treatment registry. Patients prescribed the drug for moderate to severe acute pain (post-surgical or non-surgical) will be screened on-site and enrolled in the registry after signing an eIC. These participants will be required to use the ObvioHealth app for data entry upon leaving the site. Patients will complete validated questionnaires measuring pain intensity, medication adherence, perception, and change to health status.
For in-patient participants, site staff will collect and submit required data via the ObvioHealth app.
This study has only just begun, so there are no results available at this time. However, be sure to check back soon for relevant updates.
This study is designed to understand usage pattern and tolerability, including dosing frequency and treatment duration, of an oral pain relief drug in post-operative and non-surgical patients.
This is a decentralized, prospective, randomized controlled study. 1000+ adults will be recruited throughout 17 sites across five APAC countries—including Singapore, Thailand, Malaysia, Hong Kong, and the Philippines—to form a patient treatment registry. Patients prescribed the drug for moderate to severe acute pain (post-surgical or non-surgical) will be screened on-site and enrolled in the registry after signing an eIC. These participants will be required to use the ObvioHealth app for data entry upon leaving the site. Patients will complete validated questionnaires measuring pain intensity, medication adherence, perception, and change to health status.
For in-patient participants, site staff will collect and submit required data via the ObvioHealth app.
This study has only just begun, so there are no results available at this time. However, be sure to check back soon for relevant updates.
This study is designed to understand usage pattern and tolerability, including dosing frequency and treatment duration, of an oral pain relief drug in post-operative and non-surgical patients.
This is a decentralized, prospective, randomized controlled study. 1000+ adults will be recruited throughout 17 sites across five APAC countries—including Singapore, Thailand, Malaysia, Hong Kong, and the Philippines—to form a patient treatment registry. Patients prescribed the drug for moderate to severe acute pain (post-surgical or non-surgical) will be screened on-site and enrolled in the registry after signing an eIC. These participants will be required to use the ObvioHealth app for data entry upon leaving the site. Patients will complete validated questionnaires measuring pain intensity, medication adherence, perception, and change to health status.
For in-patient participants, site staff will collect and submit required data via the ObvioHealth app.
This study has only just begun, so there are no results available at this time. However, be sure to check back soon for relevant updates.
This study is designed to understand usage pattern and tolerability, including dosing frequency and treatment duration, of an oral pain relief drug in post-operative and non-surgical patients.
This is a decentralized, prospective, randomized controlled study. 1000+ adults will be recruited throughout 17 sites across five APAC countries—including Singapore, Thailand, Malaysia, Hong Kong, and the Philippines—to form a patient treatment registry. Patients prescribed the drug for moderate to severe acute pain (post-surgical or non-surgical) will be screened on-site and enrolled in the registry after signing an eIC. These participants will be required to use the ObvioHealth app for data entry upon leaving the site. Patients will complete validated questionnaires measuring pain intensity, medication adherence, perception, and change to health status.
For in-patient participants, site staff will collect and submit required data via the ObvioHealth app.
This study has only just begun, so there are no results available at this time. However, be sure to check back soon for relevant updates.
Real World Study on Acute Pain Treatment in Adult Post-Surgical and Non-Surgical Patients. We are working with a global biopharmaceutical company known for producing advanced therapeutics and diagnostic solutions to study a well-known pain relief drug.
This study is designed to understand usage pattern and tolerability, including dosing frequency and treatment duration, of an oral pain relief drug in post-operative and non-surgical patients.
This is a decentralized, prospective, randomized controlled study. 1000+ adults will be recruited throughout 17 sites across five APAC countries—including Singapore, Thailand, Malaysia, Hong Kong, and the Philippines—to form a patient treatment registry. Patients prescribed the drug for moderate to severe acute pain (post-surgical or non-surgical) will be screened on-site and enrolled in the registry after signing an eIC. These participants will be required to use the ObvioHealth app for data entry upon leaving the site. Patients will complete validated questionnaires measuring pain intensity, medication adherence, perception, and change to health status.
For in-patient participants, site staff will collect and submit required data via the ObvioHealth app.
This study has only just begun, so there are no results available at this time. However, be sure to check back soon for relevant updates.
Real World Study on Acute Pain Treatment in Adult Post-Surgical and Non-Surgical Patients. We are working with a global biopharmaceutical company known for producing advanced therapeutics and diagnostic solutions to study a well-known pain relief drug.
This study is designed to understand usage pattern and tolerability, including dosing frequency and treatment duration, of an oral pain relief drug in post-operative and non-surgical patients.
This is a decentralized, prospective, randomized controlled study. 1000+ adults will be recruited throughout 17 sites across five APAC countries—including Singapore, Thailand, Malaysia, Hong Kong, and the Philippines—to form a patient treatment registry. Patients prescribed the drug for moderate to severe acute pain (post-surgical or non-surgical) will be screened on-site and enrolled in the registry after signing an eIC. These participants will be required to use the ObvioHealth app for data entry upon leaving the site. Patients will complete validated questionnaires measuring pain intensity, medication adherence, perception, and change to health status.
For in-patient participants, site staff will collect and submit required data via the ObvioHealth app.
This study has only just begun, so there are no results available at this time. However, be sure to check back soon for relevant updates.
ObvioHealth successfully conducted a clinical trial for RedHill Biopharma to test the safety and efficacy of an oral medication for the treatment of COVID-19 symptoms. We designed this decentralized study to be conducted where the majority of patients recover from illness—in their homes. When the trial was launched in 2021, its unique combination of home health visits, electronic patient-reported outcomes (ePRO), and remote monitoring devices was pioneering—COVID-19 studies were typically conducted inside hospitals.
ObvioHealth and Renovia conducted a groundbreaking study on the efficacy of an at-home medical device for the treatment of stress and mixed urinary incontinence. Read more below to understand how we delivered a successful, fully virtual clinical trial in the midst of the pandemic.